IOVA News and Press, Iovance Biotherapeutics Inc. From 01/23/23

Acquisition of Worldwide Rights to Proleukin ® Provides Immediate and Ongoing Revenue and Secures IL-2 Supply for Clinical and Future Commercial TIL Therapy Positive FDA Feedback on Phase 3 Confirmatory Study in Frontline Advanced (Metastatic or Unresectable) Melanoma P...

Summary In the latest conference call, Iovance Biotherapeutics, Inc. management seemed quite confident in their ability to complete the rolling of BLA for lifileucel by this quarter. I believe that previous management concerns relating to Dr. Fardis' departure are overblown by Wall Stre...

Shares of Iovance Biotherapeutics ( NASDAQ: IOVA ) dropped in the morning hours Friday after Goldman Sachs downgraded the clinical-stage biotech to Neutral from Buy, citing concerns about the company's lead asset lifileucel. The downgrade follows a ~17% gain in Iovance ( IOVA ) sh...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Despite a rough day in the market over fears that the Federal Reserve may raise interest rates and thus induce a recession, biopharmaceutical startup Iovance Biotherapeutics (NASDAQ: IOVA ) stock shot up, completely again...

Shares of biopharma company Iovance Biotherapeutics (NASDAQ: IOVA) are down 8.7% as of 12:31 p.m. ET Friday after the company announced it had received feedback from the U.S. Food and Drug Administration (FDA) regarding its new drug application for cancer treatment lifileucel. While...

SAN CARLOS, Calif., Nov. 18, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) today announced that its ongoing rolling Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) for lifileucel is expected to be completed in the first q...

Clinically Meaningful and Durable Activity in Largest Cell Therapy Clinical Trial in Patients with Melanoma After Progression on Immune Checkpoint Inhibitors 31% Objective Response Rate (ORR) and Median Duration of Response (mDOR) Not Reached at 27.6 Months Median Study Follow U...

Iovance Biotherapeutics, Inc. (IOVA) Q3 2022 Results Conference Call November 03, 2022 04:30 PM ET Company Participants Sara Pellegrino - Senior Vice President of Investor Relations and Corporate Communications Frederick Vogt - Interim President and Chief Executive O...

Iovance Biotherapeutics press release ( NASDAQ: IOVA ): Q3 GAAP EPS of -$0.63 beats by $0.01 . Iovance had $366.6M in cash, cash equivalents, investments and restricted cash at September 30, 2022, compared to $602.1 million at December 31, 2021...

First Biologics License Application (BLA) Submission Initiated and on Track to Complete in 4Q22 SAN CARLOS, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapi...